Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Curr Drug Targets. 2020 Apr 25;:
Authors: El Bairi K, Afqir S, Amrani M
Abstract
Notwithstanding important advances in the treatment of epithelial ovarian cancer (EOC), this disease is still a leading cause of global high mortality from gynecological malignancies. Recurrence in EOC is inevitable and it is responsible for poor survival rates. There is a critical need for novel effective biomarkers with improved accuracy compared to the standard carbohydrate antigen-125 (CA-125) for followup. The human epididymis protein 4 (HE4) is used for early detection of EOC (ROMA algorithm) as well as for predicting optimal cytoreduction after neoadjuvant chemotherapy and survival outcomes. Notably, the emerging HE4 is a promising prognostic biomarker that has displayed better accuracy in various recent studies for detecting recurrent disease. In this mini-review, we discuss the potential of HE4 as an accurate predictor of EOC recurrence.
PMID: 32334501 [PubMed - as supplied by publisher]
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: El Bairi K, Afqir S, Amrani M Tags: Curr Drug Targets Source Type: research
More News: Cancer | Cancer & Oncology | Carbohydrates | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | Study